Improvements to Leading ADC Platform Technologies?
Time: 6:00 pm
day: Conference Day One pt 2
Details:
• Explaining how antibody-linker stabilisation impacts the dosing, safety, and pharmacokinetics of vedotin ADCs
• Investigating diverse approaches to improvement of deruxtecan ADCs
• Forecasting validation of ADC philosophy impact in clinical trials
